Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide, and therapeutic agents for this malignancy are lacking. MicroRNAs play critical roles in carcinogenesis and present tremendous therapeutic potential. Here, we report that microRNA-206 is a robust tumor suppressor that plays important roles in the development of HCC by regulating cell-cycle progression and the cMet signaling pathway. MicroRNA-206 was underexpressed in livers of two HCC mouse models, human individuals bearing HCC, and human HCC cell lines. Combining bioinformatic prediction and molecular and cellular approaches, we identified cMET (Met proto-oncogene), cyclin D1 (CCND1), and cyclin-dependent kinase 6 (CDK6) as functional targets of microRNA-206. By inhibiting expression of cMET, CCND1, and CDK6, microRNA-206 delayed cell-cycle progression, induced apoptosis, and impaired proliferation of three distinct human HCC cell lines. Systemic administration of microRNA-206 completely prevented HCC development in both cMyc and V-Akt murine thymoma viral oncogene homolog 1/neuroblastoma RAS viral oncogene homolog (AKT/Ras) HCC mice, whereas 100% of control mice died from lethal tumor burdens. Conversely, reintroduction of cMet or Cdk6 into livers of cMyc and AKT/ Ras HCC mice recovered growth of HCC inhibited by microRNA-206. These results strongly suggested that cMet and Cdk6 were two functional targets that mediated the inhibitory effect of microRNA-206 on the development of HCC. MicroRNA-206 overexpression demonstrated a profound therapeutic effect on HCC in xenograft and cMyc HCC mice. Conclusion: In summary, this study defines a potentially critical role of microRNA-206 in preventing the growth of HCC and suggests its use as a potential therapeutic strategy for this malignancy. (HEPATOLOGY 2017;66:1952-1967.
H epatocellular carcinoma (HCC) is a very common malignant disease with more than 700,000 new patients diagnosed per year. (1) The mortality of HCC worldwide nearly matched its incidence, demonstrating the aggressive nature of this malignancy and limited therapeutic options. (1, 2) Although hepatitis B (HBV) and C (HCV) infection are the major risk factors of HCC, liver damage attributed to NAFLD (nonalcoholic fatty liver disease) is associated with the majority of HCC patients in the Western world. (3, 4) Over the past 30 years, HCC patients have tripled because of the prevalence of Abbreviations: AKT, V-Akt murine thymoma viral oncogene homolog 1; CDK, cyclin-dependent kinases; CCND1, cyclin D1; cMet, Met proto-oncogene; CRISPR/Cas9, the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9; DMEM, Dulbecco's modified Eagle's medium; EF1a, elongation factor 1 alpha; FBS, fetal bovine serum; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HITS-CLIP, high-throughput sequencing of RNAs isolated by cross-linking immunoprecipitation; MAPK, mitogen-activated protein kinase; miRNAs, microRNAs; MTT, methyl thiazolyl tetrazolium; NAFLD, nonalcoholic fatty liver disease; pCMV, cytomegalovirus promoter; Ras, neuroblastoma RAS viral oncogene homolog; SB, sleeping beauty; SEM, standard error of the mean; TP, target protector; TTR, transthyretin; 3 0 -UTR, 3 0 -untranslated region; WT, wild type. obesity and its related morbidities, including NAFLD. (1) Given the limited success with chemotherapy and the insensitivity of HCC to radiotherapy, tumor extirpation represents the only choice for longterm cure. (1, 2) Unfortunately, even with successful surgical removal, the presence of NAFLD is associated with an increased recurrence of tumor. (3, 4) Continuous efforts are needed to identify new targets and molecular pathways for drug development in the treatment of HCC.
MicroRNAs (miRNAs) are naturally occurring small noncoding RNAs that function primarily by binding to the 3 0 -untranslated regions (3 0 -UTR) of specific mRNAs, which leads to either mRNA degradation or translational pausing. (5) Accumulating evidence has shown that these small molecules play important roles in carcinogenesis, lipid metabolism, and development by repressing expression of their targets. (6) (7) (8) MiRNA profiling of HCC tumors and its adjacent benign tissues identified a number of dysregulated miRNAs in HCC. (9) (10) (11) Given their critical role in carcinogenesis, (12) these miRNAs now represent novel therapeutic agents for human cancers. However, the detailed mechanism(s) by which miRNAs modulate hepatocarcinogenesis is largely unknown and miRNA therapeutic drugs for this cancer are unavailable. Amplification and overexpression of the cMYC oncogene is a frequent event in human HCC. (13, 14) In mice, overexpression of cMyc by hydrodynamic transfection leads to rapid liver tumor formation. (15) In addition, coordinated activation of V-Akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycin and neuroblastoma RAS viral oncogene homolog (RAS)/mitogen-activated protein kinase (MAPK) cascades occurs in over 50% of all human HCCs and is associated with biological aggressiveness and poor prognosis. (16) This phenotype can be recapitulated in vivo by hydrodynamically transfecting activated forms of AKT (myr-AKT) and NRas (NRas-V12) oncogenes (AKT/Ras) into mouse liver. (16) In our previous study, we showed that all mice transfected with AKT/Ras or cMyc died by 6 to 8 weeks postinjection attributed to tumor burden. (15) In addition, cMyc and AKT/Ras-induced HCC in rodents recapitulate, in a highly reliable way, the phases of tumor initiation and progression that occur in humans. In this study, we used cMyc and AKT/Ras mice, xenograft tumor mice, and human HCC cell lines to investigate the underlying mechanisms by which miR-206 inhibits HCC, in addition to assessing its therapeutic potential for liver cancer.
Materials and Methods

CONSTRUCTION OF EXPRESSION
VECTORS FOR miR-206, AKT, Ras, cMyc, Met PROTO-ONCOGENE, CYCLIN-DEPENDENT KINASE 6, AND CYCLIN D1
A 400-base-pair fragment containing the miR-206 precursor was amplified from human genomic DNA, inserted into a pT3-EF1a (elongation factor 1 alpha) vector, and referred to as pT3-EF1a-miR-206. Construction of vectors pT3-EF1a-cMyc, (15) pT3-EF1a-myr-AKT, (15) nRasV12/pT2-CAGGS, (15) pT3-EF1a-Ccnd1 (cyclin D1), (17) pT3-EF1a-Cdk6 (cyclin-dependent kinase 6), (17) pT3-EF1a-cMet (Met proto-oncogene), (17) and cytomegalovirus promoter (pCMV)/ Sleeping Beauty transposase (pCMV/SB) (15) was carried out as described. All the plasmids used to induce HCC in wild-type (WT) FVB/N mice were purified using the Endotoxin free Maxi prep kit (Sigma-Aldrich, St. Louis, MO).
CONSTRUCTION OF A MINICIRCLE EXPRESSION VECTOR FOR miR-206
We generated a versatile expression vector of miR-206 by cloning a human miR-206 precursor region into minicircle vectors purchased from System Biosciences (Palo Alto, CA). A transthyretin gene (TTR) promoter was inserted upstream of the miR-206 precursor to ensure liver-specific expression of miR-206. (18) This new construct was referred to as MC-TTR-miR-206. To rule out nospecific effects of the plasmid, we generated a miR-206 mismatched expression vector by mutating seed region of miR-206, termed MC-TTRmiR-206-MM. To prepare minicircle vectors, parental MC-TTR-miR-206 vector was transformed into a special host Escherichia coli bacterial strain, ZYCY10P3S2T (System Biosciences). All minicircles were made based on the manufacturer's instructions.
PREPARATION OF miR-206 MIMIC
miR-206 mimic and scramble control were purchased from Creative Biogene (Shirley, NY). miR-206 mimic is a chemically modified double-strand miRNA, which can mimic mature endogenous miR-206 after transfection into cells. The antisense strand of miR-206 has two phosphorothioates at the 5 0 end, four phosphorothioates, four cholesterol groups at the 3 0 end, and fulllength nucleotide 2 0 -methoxy modification. Both miR-206 mimic and scramble control were formulated in 0.9% NaCl to a final concentration of 10 mg/mL.
ESTABLISHMENT OF AKT/Ras AND cMyc HCC MICE
Eight week old FVB/N mice (WT) were obtained from Charles River (Wilmington, MA). Standard hydrodynamic injections were performed as described. (15) To determine the inhibitory effect of miR-206 on cMyc-induced HCC, mice (n 5 10) were hydrodynamically injected with 5 lg of pT3-EF1a-cMyc and 10 lg of pT3-EF1a-miR-206 together with 0.6 lg of pCMV/SB. Control mice (n 5 10) were injected with 5 lg of pT3-EF1a-cMyc and 10 lg of pT3-EF1a together with 0.6 lg of pCMV/SB. To evaluate the effect of miR-206 on AKT/Ras-induced HCC, mice (n 5 10) were hydrodynamically injected with 4 lg of pT3EF1a-myr-AKT, 4 lg of NRasV12/ pT2-CAGGS, and 10 lg of pT3-EF1a-miR-206 together with 0.72 lg of pCMV/SB. Control mice (n 5 10) received 4 lg of pT3-EF1a-myr-AKT, 4 lg of NRasV12/pT2-CAGGS, and 10 lg of pT3-EF1a together with 0.72 lg of pCMV/SB. To examine whether cMet, Cdk6, and Ccnd1 were the functional targets of miR-206, WT FVB/N mice were randomly separated into five groups: group I mice (control group, n 5 10) were injected with a combination of 4 lg of pT3-EF1a-myr-AKT, 4 lg of NRasV12/pT2-CAGGS, 10 lg of pT3-EF1a, and 1.12 lg of pCMV/SB; group II (n 5 10) were injected with a combination of 4 lg of pT3-EF1a-myr-AKT, 4 lg of NRasV12/pT2-CAGGS, 10 lg of pT3-EF1a-miR-206, and 1.12 lg of pCMV/SB. This group was used to determine whether miR-206 was able to prevent HCC development; and group III-V (n 5 10) received 4 lg of pT3-EF1a-myr-AKT, 4 lg of NRasV12/ pT2-CAGGS, 10 lg of pT3-EF1a-miR-206, and 1.12 lg of pCMV/SB together with 10 lg of pT3-EF1a-cMet, pT3-EF1a-Cdk6, or pT3-EF1a-Ccnd1. These groups were used to determine whether additional treatment of Ccnd1, Cdk6, or cMet expression vector was able to recover the development of HCC inhibited by miR-206. The same strategy was used to determine whether cMet, Cdk6, and Ccnd1 mediated the inhibitory effect of miR-206 on HCC in cMyc mice. The plasmid mixtures were diluted in 2 mL of saline (0.9% NaCl), filtered through a 0.22-lm filter, and injected into the lateral tail vein of 6-to 8-week-old FVB/N mice in 5-7 seconds. Mice were housed, fed, and monitored in accord with protocols approved by the Committee for Animal Research at the University of California, San Francisco (San Francisco, CA) and the University of Minnesota (Minneapolis, MN). 
THERAPEUTIC MODELS OF cMyc AND AKT/Ras MICE
GLOBAL miRNA EXPRESSION PROFILING OF LIVERS OF AKT/Ras AND cMyc HCC MICE
A NanoString nCounter miRNA (NanoString Technologies, Seattle, WA) assay was used to perform miRNA profiling in livers of WT, cMyc, and AKT/ Ras mice. Total RNA was extracted from frozen liver tissues using an miRNeasy Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Only RNA samples with good RNA quality, as confirmed with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), were included for the NanoString analysis. All sample preparation and hybridization were performed according to the manufacturer's recommendations. For platform validation using synthetic oligonucleotides, NanoString nCounter miRNA raw data were normalized for lane-to-lane variation with a dilution series of six spike-in positive controls. The sum of the six positive controls for a given lane was divided by the average sum across lanes to yield a normalization factor, which was then multiplied by the raw counts in each lane to give normalized values. Normalized miRNA array data were obtained and used for the analysis. Unsupervised clustering was performed using Genesis 1.7.6 with Euclidean distance. The comparison of miRNA profiles was performed using an unpaired Student t test. miRNAs with P value <0.001 and intensity fold change 2.0 (on either tumor vs. nontumor or nontumor vs. tumor) were included in the differentially expressed miRNAs.
miR-206 EXPRESSION ANALYSIS IN HUMAN HCC TUMORS AND NORMAL TISSUES
The data set of GSE40744, which includes 19 normal livers and 26 HCC tumor samples, was downloaded from Gene Expression Omnibus database (PubMed). Signal intensity was normalized using robust multiarray average analysis in R environment before conducting the expression analysis. Another 31 pairs of human HCC tumors with adjacent normal livers were analyzed for miR-206 expression using Taqman MicroRNA Assay (Invitrogen, Carlsbad, CA; Supporting Table S1 ). The P values presented were calculated using the Student two-sample t test.
IDENTIFICATION OF miR-206 TARGETS
Identification of miR-206 target genes was conducted as previously described with minor revision. (19) Breifly, we downloaded the target gene databases of miR-206 based on TargetScan, (20) Pictar, (21) and Starbase. (22) Only hits from TargetScan or PicTar algorithm that were confirmed by Ago HITS-CLIP (high-throughput sequencing of RNAs isolated by cross-linking immunoprecipitation [HITS-CLIP] from Argonaute protein complex) were selected. These three databases were compared using Microsoft Access 2000. We then carried out Gene Ontology analysis using PathwayStudio software (Elsevier, Amsterdam, The Netherlands) and compared with established and potential therapeutic targets for HCC, (23) (24) (25) yielding six potential targets of miR-206 (Supporting Table S2 ).
XENOGRAFT TUMOR ASSAY
The xenografts were established in BALB/C nude mice (Charlies River). Huh7, SNU449, or MHCC97-H was stably transfected Plenti-CMV-puromycinmiR-206 or empty vector (control). The Huh7, SNU449, and MHCC97-H cells were placed in a sixwell plate 24 hours before transfection. Twenty-four hours after transfection, 5 3 10 5 cells in 0.1 mL of phosphate-buffered saline were injected subcutaneously into the right flank of athymic nude mice (n 5 12) to establish a model of tumor-bearing mice. Tumor growth was observed every 3 days by measuring its diameter with Vernier calipers. Tumor weight was calculated by gram. Tumor volume (cm 3 ) 5 d 2 3 D/2, where d is the shortest and D is the longest diameter, respectively. Mice were killed when the tumor size reached 1.5 cm in diameter. All procedures involving mice were approved by the Institutional Animal Care Committee at the University of California San Francisco and the University of Minnesota.
STABLE CELL LINES AND COLONY FORMATION ASSAY
Huh7, MHCC97-H, and SNU449 cells were stored in our laboratories. Plenti-CMV-puromycinmiR-206 or control plasmids together with packaging plasmids were cotransfected into human embryonic kidney 293T (HEK-293T) cells. Forty-eight hours after transfection, the supernatants were harvested and filtered through a 0.45-lm filter. Huh7, MHCC97-H, and SNU449 cells were maintained as monolayer culture in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Two days later, the cells were transfected with each lentiviral stock and were selected with puromycin for 3 days. After antibiotic selection, cells were harvested for subsequent studies. Stably transfected Huh7, MHCC97-H, and SNU449 cells were seeded in a six-well plate at appropriate density per well in triplicate. When visible cell colonies appeared, the colonies were fixed and stained with 0.1% crystal violet dissolved in methanol for 15 minutes for visualization and counting.
To determine whether CCND1, CDK6, or cMET mediates the inhibitory effect of miR-206 on colony formation, miR-206-stably transfected MHCC97-H, Huh7, and SNU-449 cells (0.5 3 10 6 cells in 35-mm plastic dishes) were transfected with Target Protector (Exiqon, Woburn, MA) of CDK6, CCND1, or cMET or scramble control (20 nM). MHCC97-H, Huh7, and SNU449 cells that were stably transfected with empty vector served as controls. Two days after transfection, the transfected cells were suspended with 8 mL of 0.4% top agar (Sigma-Aldrich) and 23DMEM supplemented with 20% FBS before being poured onto 6-cm tissue culture dishes coated with 3.5 mL of 0.7% bottom agar. Fourteen days later, three areas per plate were chosen randomly, and the number of visible colonies was counted.
STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism Software (GraphPad Software, Inc., La Jolla, CA). Data derived from cell-line experiments were presented as mean 6 standard error of the mean (SEM) and assessed by a two-tailed Student t test. Statistical difference for cell-cycle progression analysis was evaluated using a chi-squared test. The MannWhitney U test was used to evaluate the statistical significance for mouse experiments. All the experiments were repeated at least three times. P < 0.05 was considered to be statistically significant.
Results
MiR-206 IS UNDEREXPRESSED IN LIVERS OF MOUSE AND HUMAN HCC TUMORS
To identify novel miRNAs that are critical regulators of HCC development, we carried out miRNA profiling of livers from AKT/Ras (23) and cMyc (24) HCC mice. We identified 12 miRNAs that were present in livers of WT mice, but undetectable in HCC tumors of both AKT/Ras and cMyc mice (Supporting Table S3 ). To correlate these findings with human HCC, we measured expression of these 12 miRNAs in normal human hepatocytes and four HCC cell lines and observed that miR-206 was the only undetectable miRNA in HCC tumors of both AKT/Ras and cMyc mice and was also reduced in human HCC cell lines compared to normal human hepatocytes (Fig. 1A,B) . Database mining of miRNA profiles revealed that miR-206 was significantly reduced in human HCC tumors compared to normal liver tissues (Fig. 1C) .
qRT-PCR further confirmed that miR-206 was robustly reduced in another 31 human HCC tumors compared to their adjacent normal tissues (Supporting Table S1 ). Taken together, hepatic expression of miR-206 is decreased in both mouse and human HCC tumors, prompting us to select miR-206 for further characterization of its role in the pathogenesis of HCC.
CCND1, cMET, AND CDK6 ARE DIRECT TARGETS OF miR-206
To gain insight into the function of dysregulated miR-206 in HCC, we aimed to identify those mRNAs that were targeted by miR-206 and serve as its effectors in the pathogenesis of HCC. We identified putative binding sites for miR-206 within 3 0 -UTRs of six genes that were involved in carcinogenesis and lipid metabolism (Supporting Table S2 ). Among these potential targets of miR-206, cMET has been linked to tumor growth in humans and its inhibitor as a therapeutic agent for HCC has entered into clinical trials. (26) CCND1 is a major cyclin controlling cell-cycle progression from G 1 to S phase by interacting with CDK4/CDK6. (27) Our prediction, combined with these established findings, led us to speculate that CCND1, cMET, and CDK6 were the functional targets of miR-206 and that miR-206 was able to prevent the pathogenesis of HCC by modulating the cMET pathway and cell-cycle progression. MiR-206 binding sites within the 3 0 -UTRs of these three genes are conserved between humans and mice ( Fig. 2A) . Overexpression of miR-206 in HepG2 cells robustly decreased both mRNA and protein levels of CCND1, cMET, and CDK6 (Fig. 2B) , whereas antagonizing miR-206 led to adverse effects (Fig. 2C) . To establish that miR-206 directly recognizes the predicted binding sites within the 3 0 -UTRs of these three genes, we cloned their 3 0 -UTRs into a luciferase reporter vector.
As expected, inclusion of the 3 0 -UTRs of CCND1, cMET, and CDK6 into the reporter construct reduced luciferase activity upon cotransfection with miR-206 into Hepa1,6 cells (Fig. 2D) . In contrast, mutation of miR-206 binding sites within the 3 0 -UTRs of CCND1, cMET, and CDK6 was necessary to completely offset the inhibitory effect of miR-206 on luciferase activity (Fig. 2E) . We further confirmed that miR-206 inhibited expression of mouse Ccnd1, cMet, and Cdk6 by directly interacting with their respective 3 0 -UTRs (Supporting Fig. S1A-D) . In vivo, delivery of miR-206 into livers also reduced both protein and mRNA levels of these three genes ( Fig. 2F; Supporting  Fig. S1E ). Together, these experiments indicate that Ccnd1, cMet, and Cdk6 are direct targets of miR-206 both in vitro and in vivo. . The Mann-Whitney U test was used to evaluate the statistical significance. Data represent mean 6 SEM. **P < 0.01; ***P < 0.001. Abbrevaition: NL, normal liver. S2A). Sustained expression of miR-206 robustly prevented colony formation of these three liver cancer cell lines (Fig. 3A) and significantly delayed G 1 /S progression of cell cycle (Fig. 3B-D) . Methyl thiazolyl tetrazolium (MTT) assay further confirmed that miR-206 was a strong suppressor of proliferation (Fig. 3E) . To determine whether CCND1, CDK6, and/or cMET mediate the inhibitory effect of miR-206 on growth and cell-cycle transition of human liver cancer cells, we treated miR-206 stably transfected Huh7, SNU449, and MHCC97-H cells with target protector (TP) morpholinos of CCND1, CDK6, and cMET or scramble control (Supporting Fig. S2B-D) . These morpholinos were complimentary to miR-206 binding sites within the 3 0 -UTRs of CCND1, CDK6, and cMET mRNAs and prevented miR-206 from binding to the 3 0 -UTRs. (28) This design allowed us to determine whether CCND1, CDK6, and cMET mediate the effects of miR-206 on inhibiting proliferation. qRT-PCR confirmed that the TPs prevented miR-206 from binding to the 3 0 -UTRs of CCND1, CDK6, and cMET, which subsequently impaired the ability of miR-206 to inhibit expression of CCND1, CDK6, and cMET (Supporting Fig. S2B-D) . Phenotypically, 0 -UTRs of human CCND1, cMET, and CDK6 after miR-206 mimic treatment. Luciferase activity was normalized to the activity of b-galactosidase. Hepa1,6 cells transfected with scramble and the luciferase reporter constructs served as control. (F) Western blotting revealing reduced protein levels of Ccnd1, cMet, and Cdk6 after MC-TTR-miR-206 injection into mice (1.5 lg/g body weights). The control mice were treated with the same dose of MC-TTR-miR-206-MM. Data represent mean 6 SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Abbreviation: ASO, antisense oligonucleotide; NS, no significance.
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HEPATOLOGY, December 2017 treatment of cMET, CCND1, and CDK6 TPs impaired the ability of miR-206 to inhibit growth and proliferation of Huh7, SNU449, and MHCC97-H (Fig. 3F,G) . In addition, miR-206 induced apoptosis of Huh7, SNU449, and MHCC97-H cells (Supporting Fig. S3A-C) . The data support the notion that by interacting with CCND1, CDK6, and cMET, miR-206 delays cell-cycle progression, impairs proliferation, and induces apoptosis of human HCC cells lines with divergent backgrounds.
miR-206 INHIBITS GROWTH OF XENOGRAFT TUMORS FROM DIFFERENT HUMAN HCC CELL LINES
To determine whether miR-206 confers protection from human HCC tumor growth in vivo, Huh7, SNU449, and MHCC97-H cells stably transfected with miR-206 expression vector were allografted into immunocompetent male mice. Consistent with our colony formation experiments, miR-206 robustly attenuated growth of xenograft tumors from Huh7, SNU449, and MHCC97-H cells (Fig. 4A) . We also determined whether CCND1, CDK6, and cMET mediated the inhibitory effect of miR-206 on growth of xenograft tumor. Specifically, we transfected TPs of CCND1, CDK6, and cMET into Huh7, SNU449, and MHCC97-H cells stably transfected with miR-206 and then performed subcutaneous xenograft of these cells into nude mice. Indeed, miR-206 robustly inhibited growth of xenograft tumor, and the TPs treatment recovered growth of the xenograft HCC tumors (Fig.  4B) . Thus, the ability of miR-206 to inhibit growth of xenograft HCC tumor appears to occur by interacting with CCND1, cMET, and CDK6.
DELIVERY OF miR-206 INTO LIVERS COMPLETELY PREVENTED HCC DEVELOPMENT IN AKT/Ras AND cMyc MICE
We have previously reported that activation of AKT/Ras, AKT/cMET, or cMyc triggers rapid HCC development in mice, and all mice developed lethal burden of liver tumor within 6-8 weeks. (15, 29) Thus, we investigated the effect of manipulating miR-206 levels on HCC in livers of AKT/Ras and cMyc mice (Supporting Fig. S4A,B) . Our results indicated that 100% of control mice died from lethal tumor burdens by 6-8 weeks postinjection and all miR-206-treated AKT/Ras mice were healthy at this stage (Fig. 5A) . Upon dissection, no tumor nodules were observed in livers of AKT/Ras/miR-206 mice (Fig. 5A) . Mechanistically, miR-206 significantly reduced hepatic expression of Ccnd1, Cdk6, and cMet in livers of AKT/ Ras HCC mice compared to control mice (Fig. 5B) . The same results were obtained in the cMyc HCC mice, and 100% of control mice died from lethal tumor burdens by 6-8 weeks postinjection; and no tumor was detected after delivery of miR-206 into livers of cMyc HCC mice (Fig. 5C) . Delivery of miR-206 into cMyc HCC mice significantly reduced protein levels of Cdk6, Ccnd1, and cMet (Fig. 5D) . Thus, miR-206 appears to be a robust suppressor of HCC initiation and progression by targeting Ccnd1, Cdk6, and cMet in AKR/Ras and cMyc mice. Cdk6, or cMet in livers of AKT/Ras/miR-206 HCC mice (Supporting Fig. S5A-C) . Increased expression of cMet or Cdk6 recovered growth of HCC that was completely prevented by miR-206 (Fig. 6A-C) ; in contrast, reintroduction of Ccnd1 into miR-206-overexpressed AKT/Ras mice failed to recover the growth of HCC tumor that was prevented by miR-206 ( Fig. 6A-C) . Using the same strategy, we further reintroduced Ccnd1, Cdk6, and cMet into cMyc HCC mice that were treated with miR-206 (Supporting Fig.  S5D-F) . As expected, all cMyc mice died 8 weeks after injection and miR-206 administration completely prevented HCC development. Restoration of cMet or Cdk6 expression recovered growth of HCC, whereas additional treatment of Ccnd1 failed to do so (Fig. 6D-F) . Thus, only cMet and Cdk6 and not Ccnd1 were able to restore growth of HCC inhibited by miR-206 in AKT/Ras and cMyc mice. Further studies are needed to investigate the contribution of the cross-talk of miR-206 with Ccnd1 in the pathogenesis of HCC.
MiR-206 DISPLAYED THE THERAPEUTIC EFFECT ON HCC IN cMyc MICE
We next assessed the therapeutic potential of miR-206 for treatment of HCC in both cMyc and AKT/ Ras HCC mice. For this purpose, we generated an miR-206 in vivo expression system using a minicircle episomal DNA vector. (30) Minicircles are episomal DNA vectors that are produced as circular expression cassettes devoid of any bacterial plasmid DNA backbone. (31) Their smaller molecular size enables more efficient delivery and offers sustained expression over a period of weeks as compared to standard plasmid vectors that only work for a few days after injection into mice. The TTR promoter was used to ensure hepatocyte-specific expression of miR-206, (15, 32) and the construct was referred to as MC-TTR-miR-206. FVB/N mice, which had been injected with AKT/Ras or cMyc to induce HCC for 2 weeks, were treated with either MC-TTR-miR-206 or MC-TTR-miR-206-MM weekly for another 4 weeks (Supporting Fig.  S6A,B) . The results showed that 4 weeks of MC-TTR-miR-206 treatment was markedly effective against HCC in cMyc mice (Fig. 7A,B) . Surprisingly, MC-TTR-miR-206 failed to repress growth of HCC in AKT/Ras mice (Supporting Fig. S7A, B) . To explore this observation, we determined levels of miR-206 in livers of AKT/Ras mice treated with either MC-TTR-miR-206-MM or MC-TTR-miR-206. Interestingly, MC-TTR-miR-206 treatment led to increased miR-206 levels and reduced mRNA levels of its targets, including Ccnd1, Cdk6, and cMet, in HCC tumors of cMyc mice compared to control mice (Fig.  7C) . In contrast, levels of miR-206 and its targets, Ccnd1, Cdk6, and cMet, showed no significant change in HCC tumors of AKT/Ras mice treated with MC-TTR-miR-206 (Supporting Fig. S7C ). The results suggested that poor delivery of the MC-TTR-miR-206 might be responsible for the negligible therapeutic effect on HCC in ATK/Ras mice, perhaps attributed to rapid growth of the HCC or other unknown mechanisms.
To increase the delivery efficiency of miR-206 into HCC tumors, we generated a miR-206 doublestranded mimic whose size was much smaller than MC-TTR-miR-206. The miR-206 mimic was further modified at 2 0 O-methyl and labeled with four cholesterol groups to increase the stability and transfection efficiency of miR-206 mimic. The same cMyc and AKT/Ras HCC mouse models described above were used to evaluate the therapeutic effectiveness of miR-206 mimic for treatment of HCC. Specifically, mice received a systemic treatment of miR-206 mimic twice for 4 weeks. When HCC tumors became invisible (around 2 weeks after AKT/Ras or cMyc injection), mice were randomized and systemically treated, by tail vein, with either miR-206 mimic or scramble control at the same dose of 10 mg/kg body weight. Following eight injections, a significant antitumor effect of miR-206 was observed in cMyc HCC mice (Fig. 7D) . Moreover, the tumor number was much smaller in cMyc mice treated with miR-206 compared to scramble treated mice (Fig. 7E) . We further evaluated the delivery efficiency of miR-206 by determining mRNA levels of its targets, including Ccnd1, Cdk6, and cMet. As expected, we observed a significant reduction in mRNA levels of these three targets in tumors treated with miR-206 as compared to controls (Fig. 7F) . In AKT/Ras mice, miR-206 mimic treatment failed to stop the rapid growth of HCC tumors and did not display any therapeutic effect on HCC (Supporting Fig.  S7D,E) . In addition, mRNA levels of miR-206's targets, including Cncd1, Cdk6, and cMet, had no change in livers of miR-206-treated mice compared to control mice (Supporting Fig. S7F ).
Discussion
The incidence rate of HCC has been increasing in the United States for the past 35 years, attributed in large part to the prevalence of obesity. (33) Recent studies revealed that postoperative morbidity and 30-day mortality rates are significantly higher in obesityassociated HCC patients than in those cases caused by HBV and HCV. (3, 4) Although HCC has been widely investigated, the underlying mechanisms are still poorly understood because of complexity of the disease. As a result, only a single chemotherapy drug (sorafenib) is available for HCC. Unfortunately, sorafenib only improves life expectancy by approximately 3 months over placebo, (34) underscoring the importance of identifying new targets and molecular pathways for the treatment of HCC. In this study, we identified a specific miRNA, miR-206 that can simultaneously inhibit expression of several therapeutic targets of HCC; and delivery of miR-206 into livers showed the robust therapeutic effect on HCC. Our findings represent evidence for the role of miR-206 in the pathogenesis of HCC and its use as a potential therapeutic agent for this malignancy.
Identification of functional targets is the key step to study the function of miR-206 in the pathogenesis of HCC. With the development of deep sequencing and HITS-CLIP techniques, many targets of miR-206 have been identified. (35) (36) (37) Therefore, it is important to elucidate which target mediates the function(s) of a specific miRNA. In this study, we used the TP technique to prevent the interaction of miR-206 with its targets CCND1, CDK6, and cMET. (38) Using this approach, we have validated CCND1, CDK6, and cMET as functional and potentially therapeutic targets of miR-206. Despite the accuracy of the TP technique to prevent miRNAs from binding to their targets, the high cost of TP is a challenge for mouse experiments. CRISPR/Cas9 technique is another potential choice to study the cross-talk of miR-206 with CCND1, CDK6, and cMET. (39) This approach can be used to delete or mutate the seed regions within the 3 0 -UTRs of target genes, which will allow us to more accurately investigate whether the interaction between miR-206 and its targets, CCND1, CDK6, and cMET, modulates the growth of hepatic carcinoma.
In 2009, we first identified miR-206 as a potential tumor suppressor in liver cancer. (6) Since then, miR-206 has been identified as an underexpressed miRNA in human breast cancer, (40) colorectal cancer, (41) and lung squamous-cell carcinoma, (42) and the function of miR-206 was investigated in cancer cell lines. To date, there are no reported studies that have been performed to evaluate the therapeutic potential of miR-206 and its efficacy in preventing HCC in mice. (43) In the present study, we validated that miR-206 was able to inhibit growth and cell-cycle progression and induce apoptosis. Notably, our data provided evidence that miR-206 has the capacity to robustly prevent the development of HCC in two HCC mouse models. As described above, miR-206 is reduced and its targets are increased in other types of human cancers. Our findings, combined with those of others, suggest that miR-206 might be a broad-spectrum anticancer agent that can be applied for other types of human cancers.
To further evaluate the therapeutic potential of miR-206 on HCC, we overexpressed miR-206 in livers of cMyc and AKT/Ras mice bearing HCC tumors using the minicircle expression vector of miR-206 or cholesterol and methyl-modified miR-206 mimic. Consistent with the strong prevention effect of miR-206 on HCC, both MC-TTR-miR-206 and miR-206 mimic treatment showed the obvious therapeutic effect on HCC in cMyc mice, but not in AKT/Ras mice. We also observed that growth of HCC tumors was much faster in AKT/Ras mice than cMyc mice (data not shown), suggesting that rapid growth of HCC might have impaired the delivery of MC-TTR-miR-206 and miR-206 mimic into tumors of AKT/Ras mice. Indeed, qRT-PCR revealed that levels of miR-206 and its targets showed no change in livers of AKT/ Ras mice treated with MC-TTR-miR-206 or miR-206 mimic compared to control mice, further indicating that the low delivery efficiency of miR-206 or other unknown mechanism(s) may contribute to the negligible therapeutic effect on HCC in AKT/Ras mice. Further studies are needed to optimize the delivery of miR-206 and investigate whether miR-206 can lead to a regression of HCC tumor in AKT/Ras mice. In summary, both in vitro and in vivo data obtained in this study could contribute to the translation of miR-206 into a therapeutic agent for the treatment of HCC. In addition, the majority of HCC patients have elevated expression of CCND1, CDK6, and/or cMET, (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) and some inhibitors of cMET and CCND1/CDK6 are being tested in clinical trials as therapeutic agents for HCC, (26, 46) further providing evidence that miR-206 may have great therapeutic potential against a broad range of human HCCs.
The pathogenesis of HCC is very complex and the detailed mechanisms of this process remain to be investigated. We have shown that miR-206 strongly prevented the development of HCC in two HCC mouse models. However, we cannot rule out that other targets of miR-206 might contribute to the pathogenesis of HCC. Thus, our next step will be to use a modified HITS-CLIP combined by MiR-Trap, (47) biotinlabeled mimics of miR-206 and RNA sequencing to identify targetome of miR-206 in livers of both AKT/ Ras and cMyc HCC mice, which will allow us to provide a comprehensive and more accurate understanding for the role of miR-206 in hepatocarcinogenesis.
